University of California

Other

Louisiana State University and Agricultural & Mechanical College

Walter and Eliza Hall Institute of Medical Research

Heike Wulff

K George Chandy

Jonathan Bayldon Baell

Andrew J Harvey

Nichole Coleman

Ananthakrishnan Sankaranarayanan

Wolfram Haensel

Alexander Schmitz

Kristina Schmidt-Lassen

Raymond Stanley Norton

David Paul Jenkins

Wolfram Hansel

Ralf Kohler

George K Chandy

Vikrant Singh

Brandon M Brown

Latika Singh

Heesung Shim

Jeffrey Erickson

Ralf Koehler

Joachim Hoyer

Aida Olivan-Viguera

Julia Vennekamp

Stephan Grissmer

This invention is directed to neuroprotective compositions and methods of using the same to treat neurodegenerative diseases.

Neuroprotective compositions and methods of using the same

Benzoxazole and indole type KCa3.1 activators as well as the therapeutic uses of such compounds in human or animal subjects and their use in ex vivo preservation of organs or tissues.

Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use

The present invention provides methods for treating seizure disorders. The method includes administering to a subject in need thereof 2-amino-6-trifluoromethylthio-benzothiazole, or a pharmaceutically acceptable salt thereof. Methods for the treatment of pain are also described.

Methods for treating seizure disorders and pain

Compositions of matter comprising 5-phenoxyalkoxypsoralen compounds and their method of synthesis and use. The compounds are useable to treat diseases or disorders in human or animal subjects, including autoimmune diseases. The compounds inhibit potassium channels, including the Kv1.3 channel and at least some of the therapeutic effects of such compounds may be due at least in part to potassium channel inhibition. In some embodiments, the compounds are more selective for certain potassium channels (e.g., Kv1.3 channels) than other potassium channels (e.g., Kv1.5 channels).

5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel

The invention relates to compounds of Formula (1) for use in modulating potassium channel activity in cells.

Potassium channel blockers and uses thereof

Methods, compositions and devices for inhibiting neoproliferative changes in blood vessel walls or other anatomical structures. One or more compounds of Formula I or I-A set forth herein are administered systemically and/or locally to human or veterinary patients to deter or prevent unwanted proliferative changes in blood vessels or other anatomical structures. The invention may be used to deter or prevent stenosis or restenosis of arteries following angioplasty and/or stent placement. In one embodiment, there is provided an implantable stent or stent graft from which one or more compounds of the present invention will elute or otherwise be delivered into an affected blood vessel wall.

Methods for inhibiting neoproliferative changes in blood vessel walls

Compositions of matter comprising 5-phenylalkoxypsoralen compounds and their method of synthesis and use. The compounds are useable to treat diseases or disorders in human or veterinary patients, including autoimmune diseases such as multiple sclerosis. The compounds inhibit potassium channels, including the Kv1.3 channel and at least some of the therapeutic effects of such compounds may be due at least in part to potassium channel inhibition.

Substituted 5-alkoxypsoralens as inhibitors of potassium channel activity in lymphocytes and other cells

[object Object]

Various divalent ligands based on khellinone derivatives are described. These derivatives can be useful in the modulation of potassium channel activity in cells, including among others Kv1.3 channels found in T-cells. The compounds may also be useful in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis.

Therapeutic ion channel blocking agents and methods of use thereof

Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated Kchannel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Caactivated Kchannel (IKCa1) prevents the pre-Castage of cell activation and thus causes immunosuppression and an anti-inflammatory response.

Non-peptide inhibition of T-lymphocyte activation and therapies related thereto

Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-&lsqb;(2-chlorophenyl)diphenylmethyl&rsqb;-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K channel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca activated K channel (IKCa1) prevents the pre-Ca stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.

Growing community of inventors

Davis, CA, United States of America

Heike Wulff